• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Case report: An uncommon presentation of extramedullary plasmacytoma without a concurrent diagnosis of multiple myeloma

by | Jun 24, 2024 | Publications

Front Oncol. 2024 Jun 7;14:1353943. doi: 10.3389/fonc.2024.1353943. eCollection 2024. ABSTRACT INTRODUCTION: Extramedullary plasmacytoma (EMP) is an uncommon solitary tumor originating from neoplastic plasma cells located outside the bone marrow. Despite its rarity,...

The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma

by | Jun 24, 2024 | Publications

Clin Lymphoma Myeloma Leuk. 2024 May 31:S2152-2650(24)00223-4. doi: 10.1016/j.clml.2024.05.022. Online ahead of print. ABSTRACT INTRODUCTION: Existing literature suggests that women are significantly underrepresented in the field of hematology-oncology. Women make up...

IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma

by | Jun 22, 2024 | Publications

Cancer Cell. 2024 Jun 14:S1535-6108(24)00217-4. doi: 10.1016/j.ccell.2024.05.026. Online ahead of print. ABSTRACT Multiple myeloma (MM) is an incurable plasma cell malignancy that exploits transcriptional networks driven by IRF4. We employ a multi-omics approach to...

CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma

by | Jun 21, 2024 | Publications

Leukemia. 2024 Jun 20. doi: 10.1038/s41375-024-02303-w. Online ahead of print. ABSTRACT Multiple myeloma (MM) cells effectively escape anti-tumoral immunity to survive in the tumor microenvironment (TME). Herein, we identify non-classical major histocompatibility...

Visualization of Keratopathy Associated With the Antibody-Drug Conjugate Belantamab Mafodotin Using Infrared Imaging in Patients With Multiple Myeloma

by | Jun 20, 2024 | Publications

Cornea. 2024 Jun 18. doi: 10.1097/ICO.0000000000003596. Online ahead of print. ABSTRACT PURPOSE: The treatment of patients with relapsed/refractory multiple myeloma (RRMM) with the antibody-drug conjugate belantamab mafodotin is affected by ocular adverse effects,...

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

by | Jun 20, 2024 | Publications

Oncology (Williston Park). 2024 Jun 10;38(6):239-241. doi: 10.46883/2024.25921023. ABSTRACT The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials. PMID:38899981 | DOI:10.46883/2024.25921023
« Older Entries
Next Entries »

Recent Content

  • Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
  • FDA OK’s belantamab mafodotin-blmf for multiple myeloma
  • Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value
  • (no title)
  • (no title)
  • (no title)
  • Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study
  • (no title)
  • Prospective systematic classification of causes of death in the course of multiple myeloma
  • Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT